AbbVie has agreed to pay $65 million on an option deal with start-up Gilgamesh Pharma, lining up rights to neuroplastogen compounds that can improve neuroplasticity - the
The recent acquisition of ImmunoGen by AbbVie, which followed the earlier acquisition of Seagen by Pfizer, has brought renewed attention to antibody-drug conjugates (ADCs), highlighting the
Cerevel Therapeutics’ Parkinson’s disease therapy tavapadon has shown efficacy in a phase 3 trial, reinforcing its blockbuster potential and no doubt delighting AbbVie, wh
Roche’s CD20xCD3 bispecific antibody Columvi has improved survival when used as a second-line therapy for diffuse large B-cell lymphoma (DLBCL) in a phase 3 trial, setting
AbbVie’s Aquipta has become the first once-daily oral therapy for both chronic and episodic migraine prevention to be recommended by NICE for NHS patients in England and W
AbbVie has made another bolt-on deal in the immunology and inflammation category, paying $48 million upfront for rights to an antibody in preclinical development at OSE Im
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.